Project Optimus: helping or hindering cancer drug development? [Yahoo! Finance]
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Stifel Nicolaus from $120.00 to $130.00. They now have a "buy" rating on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $125.00 price target on the stock.